Engineered immune cells take on breast cancer

NCT ID NCT04430595

Recruiting now Disease control Sponsor: Shenzhen Geno-Immune Medical Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment using specially engineered immune cells (4SCAR-T cells) that target three different markers on breast cancer cells: GD2, Her2, and CD44v6. The goal is to see if this approach is safe and can shrink tumors in people with advanced or relapsed breast cancer. Up to 100 adults aged 18 to 75 with stage III, IV, or relapsed breast cancer will receive infusions of these cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 4SCAR-T cells targeting GD2, Her2, and CD44v6
What this could lead to: If it works, this could offer a new treatment option for advanced breast cancer that has not responded to standard therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 100 participants, so results may not apply to all patients. CAR-T therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Shenzhen Geno-immuno Medical Institute
RECRUITING

Shenzhen, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.